Back

Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis

Rogers, G.; Landi, S.; Purssell, H.; Momoh, T.; Yates, S.; Street, O.; Piper Hanley, K.; Hanley, N.; Athwal, V.; Payne, K.

2025-06-02 health economics
10.1101/2025.06.01.25328671 medRxiv
Show abstract

ABSTRACTO_ST_ABSBackgroundC_ST_ABSWe urgently need innovative strategies to combat a growing epidemic of chronic liver disease (CLD). ID-LIVER was a collaborative project aiming to improve detection of reversible-stage CLD in a region with high prevalence of critical risk factors. ObjectiveTo determine the cost-effectiveness of ways to identify people with significant CLD, including proactive case-finding in the community (supplementing reactive referrals from primary care) and/or risk-stratification (using FIB-4 or ID-LIVER-ML -- a novel machine-learning risk-stratification tool). DesignState-transition decision-analytic model estimating lifetime healthcare costs (2023/24 GBP) and quality-adjusted life-years (QALYs) associated with six alternative strategies for case-finding and risk-stratification. We simulated cohorts of people with alcohol-related liver disease (ARLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). We populated the model with data collected in ID-LIVER, supplemented by parameters from literature and routine data-sources. We estimated incremental cost-effectiveness and performed deterministic and probabilistic sensitivity analyses. ResultsAny case-identification strategy costing [≤]3,300 GBP per person with significant CLD identified would meet English cost-effectiveness thresholds (20,000 GBP/QALY). In our decision-set, the cheapest strategy is to use FIB-4 in the reactive-only population. ID-LIVER-ML generates more population health at reasonable cost (10,490 GBP/QALY gained). Introducing proactive case-finding generates further health benefits, costing 12,952 GBP/QALY gained. Using ID-LIVER-ML in the proactive-and-reactive population has the highest probability of maximising cost-effectiveness, when valuing QALYs at 20,000 GBP. ConclusionSmart methods of case-finding and risk-stratification identify people with significant CLD in the community, and are likely to represent good value for money in England.

Published in BMJ Public Health · training set

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.